ABCG2 gene amplification and expression in esophageal cancer cells with acquired adriamycin resistance

Liu,Liang; Zuo,Lian Fu; Guo,Jian Wen

doi:10.3892/mmr.2014.1949

ABCG2 gene amplification and expression in esophageal cancer cells with acquired adriamycin resistance

Authors:
- Liang Liu
- Lian Fu Zuo
- Jian Wen Guo
View Affiliations

Affiliations: Department of Flow Cytometry Analysis, Tumor Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
Published online on: February 13, 2014 https://doi.org/10.3892/mmr.2014.1949
Pages: 1299-1304

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resistance to chemotherapeutic agents is the main reason for treatment failure in patients with cancer. The primary mechanism of multidrug resistance (MDR) is the overexpression of drug efﬂux transporters, including ATP‑binding cassette transporter G2 (ABCG2). To the best of our knowledge, the MDR mechanisms of esophageal cancer have not been described. An adriamycin (ADM)‑resistant subline, Eca109/ADM, was generated from the Eca109 esophageal cancer cell line by a stepwise selection in ADM from 0.002 to 0.02 ng/µl. The resulting subline, designated Eca109/ADM, revealed a 3.29‑fold resistance against ADM compared with the Eca109 cell line. The ABCG2 gene expression in the Eca109/ADM cells was increased compared with that of the Eca109 cells. The cellular properties of the Eca109/ADM cells were detected by reverse transcription polymerase chain reaction (RT‑PCR), flow cytometry and western blotting. The ABCG2 expression levels were detected by RT‑PCR and flow cytometry, and the drug efflux effect was detected by flow cytometry. The present study detected the correlation between ABCG2 and the multidrug resistance of esophageal cancer. ABCG2 gene expression and the drug efflux effect of the Eca109/ADM cells were increased compared with those of the Eca109 cells. Collectively, the results of this study indicated that the overexpression of ABCG2 in the Eca109/ADM cells resulted in drug efflux, which may be responsible for the development of esophageal cancer MDR.

View Figures

View References

1	Ding R, Shi J, Pabon K and Scotto KW: Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance. Mol Pharmacol. 81:328–337. 2012. View Article : Google Scholar : PubMed/NCBI
2	Ishikawa T, Saito H, Hirano H, Inoue Y and Ikegami Y: Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance. Methods Mol Biol. 910:267–278. 2012. View Article : Google Scholar : PubMed/NCBI
3	Kalalinia F, Elahian F, Hassani M, Kasaeeian J and Behravan J: Phorbol ester TPA modulates chemoresistance in the drug sensitive breast cancer cell line MCF-7 by inducing expression of drug efflux transporter ABCG2. Asian Pac J Cancer Prev. 13:2979–2984. 2012. View Article : Google Scholar : PubMed/NCBI
4	Mo W and Zhang JT: Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol. 3:1–27. 2012.PubMed/NCBI
5	Natarajan K, Xie Y, Baer MR and Ross DD: Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol. 83:1084–1103. 2012. View Article : Google Scholar : PubMed/NCBI
6	Sodani K, Tiwari AK, Singh S, et al: GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochem Pharmacol. 83:1613–1622. 2012. View Article : Google Scholar : PubMed/NCBI
7	Wu CP, Hsieh CH and Wu YS: The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Mol Pharm. 8:1996–2011. 2011. View Article : Google Scholar : PubMed/NCBI
8	Xia CQ and Smith PG: Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation. Mol Pharmacol. 82:1008–1021. 2012. View Article : Google Scholar : PubMed/NCBI
9	Oguri T, Ozasa H, Uemura T, et al: Preclinical rationale for synergistic interaction of pemetrexed and cytotoxic nucleoside analogues. Oncol Lett. 4:571–575. 2012.PubMed/NCBI
10	Oplustilova L, Wolanin K, Mistrik M, et al: Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle. 11:3837–3850. 2012. View Article : Google Scholar : PubMed/NCBI
11	Spanswick VJ, Lowe HL, Newton C, et al: Evidence for different mechanisms of ‘unhooking’ for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. BMC Cancer. 12:4362012.
12	Yang YI, Lee KT, Park HJ, et al: Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway. Carcinogenesis. 12:2488–2498. 2012.PubMed/NCBI
13	Hagiya Y, Endo Y, Yonemura Y, et al: Pivotal roles of peptide transporter PEPT1 and ATP-binding cassette (ABC) transporter ABCG2 in 5-aminolevulinic acid (ALA)-based photocytotoxicity of gastric cancer cells in vitro. Photodiagnosis Photodyn Ther. 9:204–214. 2012. View Article : Google Scholar : PubMed/NCBI
14	Flores-Martín J, Rena V, Márquez S, Panzetta-Dutari GM and Genti-Raimondi S: StarD7 knockdown modulates ABCG2 expression, cell migration, proliferation, and differentiation of human choriocarcinoma JEG-3 cells. PLoS One. 7:e441522012.PubMed/NCBI
15	Shen B, Dong P, Li D and Gao S: Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines. Exp Ther Med. 2:1151–1157. 2011.PubMed/NCBI
16	Doyle L and Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 22:7340–7358. 2003. View Article : Google Scholar : PubMed/NCBI
17	Omran OM: The prognostic value of breast cancer resistance protein (BCRP/ABCG2) expression in breast carcinomas. J Environ Pathol Toxicol Oncol. 31:367–376. 2012. View Article : Google Scholar : PubMed/NCBI
18	Campos CR, Schröter C, Wang X and Miller DS: ABC transporter function and regulation at the blood-spinal cord barrier. J Cereb Blood Flow Metab. 32:1559–1566. 2012. View Article : Google Scholar : PubMed/NCBI
19	Decleves X, Jacob A, Yousif S, Shawahna R, Potin S and Scherrmann JM: Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. Curr Drug Metab. 12:732–741. 2011. View Article : Google Scholar : PubMed/NCBI
20	Kania KD, Wijesuriya HC, Hladky SB and Barrand MA: Beta amyloid effects on expression of multidrug efflux transporters in brain endothelial cells. Brain Res. 1418:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
21	Masereeuw R and Russel FG: Regulatory pathways for ATP-binding cassette transport proteins in kidney proximal tubules. AAPS J. 14:883–894. 2012. View Article : Google Scholar : PubMed/NCBI
22	Miller DW, Hinton M and Chen F: Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers. Neurourol Urodyn. 30:1633–1638. 2011. View Article : Google Scholar : PubMed/NCBI
23	Pinzón-Daza M, Garzón R, Couraud P, et al: The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells. Br J Pharmacol. 167:1431–1447. 2012.PubMed/NCBI
24	Kobayashi D, Ieiri I, Hirota T, et al: Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos. 33:94–101. 2005. View Article : Google Scholar : PubMed/NCBI
25	Krishnamurthy P and Schuetz JD: Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol. 46:381–410. 2006. View Article : Google Scholar : PubMed/NCBI
26	Pan G, Giri N and Elmquist WF: Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos. 35:1165–1173. 2007. View Article : Google Scholar : PubMed/NCBI
27	Mao Q and Unadkat JD: Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 7:E118–E133. 2005. View Article : Google Scholar : PubMed/NCBI